Boehringer Ingelheim Confident Of A Happier Ending In NASH Than HCV

With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking its time to investigate a variety of approaches to the multi-factorial disease.